Preeclampsia is formerly known as toxemia. Preeclampsia occurs when women have high blood pressure and possibly protein in urine during pregnancy or after delivery. Preeclampsia may result in damage to the kidneys, liver, lung, heart, or eyes, and may cause a stroke or other brain injury. Preeclampsia can lead to eclampsia, a serious condition that can have health risks for both mother and baby and in rare cases can even cause death. If preeclampsia leads to seizures, then women have eclampsia. Symptoms of preeclampsia include persistent headache, abnormal swelling in hands and face, sudden weight gain, changes in vision, and pain in the right upper abdomen. The only cure for preeclampsia is to give birth. Even after delivery, symptoms of preeclampsia can last 6 weeks or more.
Market Dynamics Key players in the market are focusing on growth strategies such as agreements, collaborations, and product launches, which are expected to drive the market growth during the forecast period. For instance, in February 2016, Diabetomics, Inc., a privately-held global medical diagnostics company, announced that the company had entered into a licensing and distribution agreement for a clinical test with BD (Becton, Dickinson and Company), a leading global medical technology company to conduct a newly developed pregnancy specific metabolic assay for the early detection of preeclampsia and gestational diabetes. In March 2015, Siemens Healthineers AG launched two new advanced urine testing solutions for the U.S. central laboratories, namely, the CLINITEK Novus Automated Urine Chemistry Analyzer and the CLINITEK AUWi PRO Automated Urine Workstation. Request For PDF: https://www.coherentmarketinsights.com/insight/request-pdf/4606 Increasing prevalence of preeclampsia is expected to drive the market growth during the forecast period. Increasing perinatal and maternal morbidity & mortality rate is set to surge the need for the early diagnosis of preeclampsia worldwide among pregnant women, which is expected to drive the global preeclampsia diagnostics market growth over the forecast period. For instance, according to the Preeclampsia Foundation, over 10 million women globally develop preeclampsia every year, and approximately 2.5 million preterm birth are caused by preeclampsia annually. The disorder is affecting both neonates and mothers in the developed and developing nations. Global Preeclampsia Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 212 million infected individuals worldwide as of August 24 2021. COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another. Buy This Premium Report: https://www.coherentmarketinsights.com/insight/buy-now/4606 Key Players Major players operating in the global preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc. About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Phone: US +12067016702 / UK +4402081334027 Email: [email protected]
0 Comments
Wound is circumscribed injury caused by an external force, which involves injury to any tissue or organ. On the basis of severity of injury, wounds are classified into acute and chronic wounds. Wounds imposes significant impact on the health of patients, which leads to pain, loss of function and mobility, depression, anxiety, and stress. According to the National Health Services (NHS), England, annual cost of maintaining wounds and associated disease conditions is US$ 6.60 billion in the U.K. In 2016, around 2.2 million population accounted to have wound and about 30% wounds lacked the diagnosis treatment in the U.K. by General Physician (GP) report. Pressure ulcer account for around US$ 1.7 million to US$ 2.6 million annually in the U.K., which is same as 4% of total NHS expenditure in 2016.
Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1205 The global wound closure market is estimated to be valued at US$ 1.4 Billion in 2017 and is expected to witness a CAGR of 7.1% during the forecast period (2017 – 2025). Increasing prevalence of diabetes and diabetes associated ulcers are expected to fuel the growth of market Diabetes foot ulcer is major cause of disability, morbidity and mortality among diabetes patients and estimated that 15% of all people with diabetes are expected to suffer from an ulcer at some stage of their life. The increased rate of diabetes and associated diabetes foot ulcers are expected to boost the growth of the wound closure market over the forecast period. According to the International Diabetes Federation (IDF) Diabetes Atlas 2017, diabetes is among the top ten causes of mortality globally. Diabetes along with major chronic diseases such as cardiovascular disease, cancer and respiratory disease, accounted for 80% of all premature NCD deaths worldwide. Moreover, around 425 million (8.8%) people worldwide, which includes adults of 20-79 year age are estimated to have diabetes. In addition, in 2016, around 87% to 91% of all people with diabetes form the high income countries are estimated to have type 2 diabetes, according to the same source. According to the study published in the Journal of Diabetes Research 2017, diabetes mellitus is most important and common metabolic disorder affecting around 2-5% of the population in the Europe, and the incidence of diabetes mellitus are expected to account for 366 million by 2030, Market Dynamics The wound closure market is gaining significant traction due to increasing cases of surgical wounds, Ulcers, and associated cases of surgical site infections (SSIs) incidences. For instance, according to the data published in the National Center for Biotechnology Information (NCBI) in April 2016, diabetic foot Ulcers is a chronic complication of diabetes mellitus and it accounted to lifetime risk of developing foot Ulcers in a patient with diabetes ranges from 15% to 25%. Moreover the increasing incidences of diabetes mellitus is expected to fuel the growth of wound closure market. Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1205 Key companies covered as a part of this study include Acelity L.P.Inc., Smith & Nephew plc, Johnson & Johnson, Braun Melsungen AG, ConvaTec Group plc, Baxter International Inc., Integra LifeSciences Corporation, Medtronic plc, Molnlycke Health Care AB, and Cardinal Health, Inc. About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] |
|